The Impact of Prophylactic Post-Chemotherapy G-CSF on the Relapse Rates in Patients with Acute Myeloid Leukemia: A Meta-Analysis

被引：2
作者：
Bordbar, Mohammadreza [1 ]
Hosseini-Bensenjan, Mahnaz [1 ]
Sayadi, Mehrab [2 ]
Zekavat, Omidreza [1 ]
Bordbar, Shayan [3 ]
Nozari, Farnoosh [1 ]
Haghpanah, Sezaneh [1 ]
机构：
[1] Shiraz Univ Med Sci, Hematol Res Ctr, Shiraz, Iran
[2] Shiraz Univ Med Sci, Cardiovasc Res Ctr, Shiraz, Iran
[3] Shiraz Univ Med Sci, Student Res Ctr, Shiraz, Iran
来源：
CANCER INVESTIGATION | 2024年 / 42卷 / 06期
关键词：
Acute myeloid leukemia; granulocyte colony-stimulating factor; relapse; survival; meta-analysis; COLONY-STIMULATING FACTOR; HEMATOPOIETIC GROWTH-FACTORS; ACUTE MYELOGENOUS LEUKEMIA; PLACEBO-CONTROLLED TRIAL; INDUCTION CHEMOTHERAPY; FEBRILE NEUTROPENIA; RANDOMIZED-TRIAL; ELDERLY-PATIENTS; DOUBLE-BLIND; CELL-CYCLE;
D O I：
10.1080/07357907.2024.2352454
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
This meta-analysis evaluated the impact of prophylactic post-chemotherapy granulocyte colony-stimulating factor (G-CSF) in patients with acute myeloid leukemia (AML). Overall, the relapse rate, overall survival, event-free survival, and mortality rate were similar in G-CSF (+) compared to G-CSF (-) patients. However, the relative risk (RR) of relapse was higher in children and in secondary AML patients who were treated with G-CSF compared to the G-CSF (-) group [RR, 95% confidence interval: 1.26, 1.04-1.52, and 1.12 (1.02-1.24)]. Treatment with post-chemotherapy G-CSF should be prescribed with caution in pediatric patients with AML and secondary AML as possibly increasing the relapse risk.
引用
收藏
页码：452 / 468
页数：17
相关论文
共 50 条
  • [21] Prophylactic Use of Granulocyte Colony-Stimulating Factor after Chemotherapy Does Not Affect Survival Rate in Acute Myeloid Leukemia: A Meta-Analysis
    Wang, Jing
    An, Li
    Chen, Shi
    Jian Ouyang
    Zhou, Rongfu
    Chen, Bing
    Yang, Yonggong
    ACTA HAEMATOLOGICA, 2009, 121 (04) : 223 - 226
  • [22] Combined chemotherapy for acute promyelocytic leukemia: a meta-analysis
    Li, Xueliang
    Wang, Chao
    Chen, Guanglong
    Ji, Buqiang
    Xu, Yongchang
    HEMATOLOGY, 2017, 22 (08) : 450 - 459
  • [23] Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia
    W. K. Hofmann
    G. Heil
    C. Zander
    S. Wiebe
    O. G. Ottmann
    L. Bergmann
    K. Hoeffken
    J. T. Fischer
    A. Knuth
    K. Kolbe
    H. J. Schmoll
    W. Langer
    M. Westerhausen
    C. B. Koelbel
    D. Hoelzer
    A. Ganser
    Annals of Hematology, 2004, 83 : 498 - 503
  • [24] Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia
    Hofmann, WK
    Heil, G
    Zander, C
    Wiebe, S
    Ottmann, OG
    Bergmann, L
    Hoeffken, K
    Fischer, JT
    Knuth, A
    Kolbe, K
    Schmoll, HJ
    Langer, W
    Westerhausen, M
    Koelbel, CB
    Hoelzer, D
    Ganser, A
    ANNALS OF HEMATOLOGY, 2004, 83 (08) : 498 - 503
  • [25] Glasdegib combined with chemotherapy in the treatment of patients with acute myeloid leukemia: a comprehensive meta-analysis
    Abdelaziz A. Awad
    Ahmed Yasser Shaban
    Fatma Mohammed
    Mohamed Mahmoud Marey
    Mohamed A. Aldemerdash
    Ahmed W. Abbas
    Omar Saeed
    Abdelrahman Saeed
    Mahmoud M. Elhady
    Israa Sharabati
    Mohamed Hamed
    Ahmed R. A. Abou-Shanab
    Ahmed Bahnasy
    Hussien Ahmed H. Abdelgawad
    Investigational New Drugs, 2025, 43 (2) : 405 - 424
  • [26] Efficacy and safety of adding gemtuzumab ozogamicin to conventional chemotherapy for adult acute myeloid leukemia: a systematic review and meta-analysis
    Guo, Yuancheng
    Deng, Lijuan
    Qiao, Yanhong
    Liu, Bei
    HEMATOLOGY, 2022, 27 (01) : 53 - 64
  • [27] Benchmarking treatment effects for patients over 70 with acute myeloid leukemia: A systematic review and meta-analysis
    Reljic, Tea
    Sehovic, Marina
    Lancet, Jeffrey
    Kim, Jongphil
    Al Ali, Najla
    Djulbegovic, Benjamin
    Extermann, Martine
    JOURNAL OF GERIATRIC ONCOLOGY, 2020, 11 (08) : 1293 - 1308
  • [28] Effectiveness and safety of granulocyte colony-stimulating factor priming regimen for acute myeloid leukemia: A systematic review and meta-analysis of the Clinical Practice Guideline for the use of G-CSF 2022 from the Japan Society of Clinical Oncology
    Najima, Yuho
    Maeda, Tomoya
    Kamiyama, Yutaro
    Nakao, Shinji
    Ozaki, Yukinori
    Nishio, Hiroshi
    Tsuchihashi, Kenji
    Ichihara, Eiki
    Miumra, Yuji
    Endo, Makoto
    Maruyama, Dai
    Yoshinami, Tetsuhiro
    Susumu, Nobuyuki
    Takekuma, Munetaka
    Motohashi, Takashi
    Ito, Mamoru
    Baba, Eishi
    Ochi, Nobuaki
    Kubo, Toshio
    Uchino, Keita
    Kimura, Takahiro
    Tamura, Shinobu
    Nishimoto, Hitomi
    Kato, Yasuhisa
    Sato, Atsushi
    Takano, Toshimi
    Yano, Shingo
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, : 899 - 910
  • [29] Venetoclax and hypomethylating agents versus induction chemotherapy for newly diagnosed acute myeloid leukemia patients: a systematic review and meta-analysis
    Yun Liu
    Ying Zhang
    Jinhong Gao
    Lijuan Wang
    Fang Xie
    Chengtao Zhang
    Peimin Mao
    Jinsong Yan
    BMC Cancer, 25 (1)
  • [30] Clinical Benefits and Safety of Gemtuzumab Ozogamicin in Treating Acute Myeloid Leukemia in Various Subgroups: An Updated Systematic Review, Meta-Analysis, and Network Meta-Analysis
    Xu, Qingyu
    He, Shujiao
    Yu, Li
    FRONTIERS IN IMMUNOLOGY, 2021, 12
12345